Hacker News: pheewma

New comment by pheewma in "Rising rates of colorectal cancer found in nearly all age groups"

pheewma — Wed, 28 Oct 2026 20:37:01 +0000

This one took a turn but point taken. You see similar arguments for a great many ailments (sperm count and carpets comes to mind). You can’t well run randomized control trials on every plastic, additive, or manufacturing process. It feels futile to even start.

New comment by pheewma in "Early progress on accelerating drug development with Claude"

pheewma — Wed, 28 Oct 2026 12:56:13 +0000

Legendary commentary track

New comment by pheewma in "Herdr is joining Y Combinator. The runtime stays open"

pheewma — Fri, 07 Aug 2026 15:55:14 +0000

They have this already. Both cmux and supacode use libghostty in the backend.

New comment by pheewma in "A love letter to flashcards"

pheewma — Fri, 10 Jul 2026 19:15:22 +0000

It depends on the subject. For classes/subjects that are very terminology-heavy, with a lot of dependencies between topics, memorizing things is a pre-requisite to the "deeper" understanding, especially under time-constraint of a semester or whatever. I think most people would agree that it's ideal to "naturally" explore a subject in order to get a deeper understanding of it, but one can't always be expected to 1. Be able to deploy that "curiosity" for all subjects at any time and 2. Be able to adequately achieve competence in a subject within the given timeframe

New comment by pheewma in "Claude Sonnet 5"

pheewma — Wed, 01 Jul 2026 13:57:02 +0000

Codex was running a 2x usage promotion from around the time when Claude introduced rate limiting during peak hours, until May 31st. The various relevant subreddits were (more) insufferable: just 1000 posts per day to the tune of "Just switched the codex! So much more usage!" only to have that tone flip immediately after the promo ran out.

New comment by pheewma in "Claude Science"

pheewma — Wed, 01 Jul 2026 13:14:46 +0000

Just to add to this: Marimo notebooks are set up in a way that ends up being easier/more-token-efficient for agents to work in. They're just python files with some custom formatting to be read by their front-end UI, sort of like cell notation in (# %%) but with a lot of QoL bells and whistles built in. Jupyter notebooks in comparison, are mostly json and are pretty messy to work with as far as git diffs goes, which is annoying. VS-Code's Github Copilot actually had pretty good Jupyter integration, letting you refer to specific cells, and allowed the agent to run individual cells and read their output before writing subsequent cells etc etc. I suspect there are vs-code specific tool calls for jupyter notebooks being used that I haven't bothered trying to replicate with claude.

A month or two ago, Marimo released Marimo Pair, which works about as well as that. It appears to be a skill that just points claude code (perhaps other harnesses, haven't tried) at whatever localhost the Marimo UI is worked off of, and tells it the structure of a Marimo notebook (very necessary since I imagine there isn't as much training data on them compared to Jupyter etc). https://marimo.io/blog/marimo-pair

New comment by pheewma in "Siri AI"

pheewma — Mon, 08 Jun 2026 19:51:21 +0000

Craig mentioned near the end of the keynote that compute intensive things (like image generation) will have rate limits that can be increased bundled with their iCloud + plans. I imagine any request that gets routed to their cloud compute will be subject to limits as well. He positioned it as a value-add to their existing subscription but I suppose that can change.

New comment by pheewma in ""AI will cure cancer" misunderstands both AI and medicine"

pheewma — Sun, 03 Mar 2024 19:14:30 +0000

There are also downstream consequences of ordering tests aside from cost; not all tests are harmless. As an example, regular screening for prostate cancer isn't recommended as much. Partially because it is often so slow-growing that people often die of other causes before the cancer even begins to cancer, and because the definitive test is a biopsy which is somewhat invasive. Rates of complications are relatively low, but it becomes a cost-benefit consideration (again, irrespective of cost) of if those risks are worth catching something that you may not even want to bother treating.